BACKGROUND: Our study describes the use of methylene blue dye as an alternative to isosulfan blue dye to identify the sentinel lymph node (SLN). METHODS: A retrospective analysis was performed of 112 breast cancer patients (113 axillae) who underwent SLN biopsy (SLNB) with methylene blue dye and (99m)Tc-labeled sulfur colloid for SLN identification. All SLNs were submitted for intraoperative frozen section analysis, hematoxylin and eosin stain, and immunohistochemical evaluation. Patients with a pathologically negative SLN did not undergo further axillary lymph node dissection. RESULTS: Of 112 patients who underwent SLNB, the SLN was identified in 107 (95.5%); 104 (92.8%) were identified by methylene blue dye. In a subset of 99 patients with recorded isotope status in relation to blue nodes, concordant identification with both dye and isotope was observed in 94 (94.9%). Of patients with identified SLNs, 32 (29.9%) of 107 contained metastatic disease, with 31 (96.9%) of 32 identified by methylene blue dye. The SLN was the only positive node in 18 (60.0%) of 30 patients. CONCLUSIONS: SLNB with methylene blue dye is an effective alternative to isosulfan blue dye for accurately identifying SLNs in breast cancer patients.
BACKGROUND: Our study describes the use of methylene blue dye as an alternative to isosulfan blue dye to identify the sentinel lymph node (SLN). METHODS: A retrospective analysis was performed of 112 breast cancerpatients (113 axillae) who underwent SLN biopsy (SLNB) with methylene blue dye and (99m)Tc-labeled sulfur colloid for SLN identification. All SLNs were submitted for intraoperative frozen section analysis, hematoxylin and eosin stain, and immunohistochemical evaluation. Patients with a pathologically negative SLN did not undergo further axillary lymph node dissection. RESULTS: Of 112 patients who underwent SLNB, the SLN was identified in 107 (95.5%); 104 (92.8%) were identified by methylene blue dye. In a subset of 99 patients with recorded isotope status in relation to blue nodes, concordant identification with both dye and isotope was observed in 94 (94.9%). Of patients with identified SLNs, 32 (29.9%) of 107 contained metastatic disease, with 31 (96.9%) of 32 identified by methylene blue dye. The SLN was the only positive node in 18 (60.0%) of 30 patients. CONCLUSIONS: SLNB with methylene blue dye is an effective alternative to isosulfan blue dye for accurately identifying SLNs in breast cancerpatients.
Authors: Alisha V DSouza; Jonathan T Elliott; Jason R Gunn; Richard J Barth; Kimberley S Samkoe; Kenneth M Tichauer; Brian W Pogue Journal: Biomed Opt Express Date: 2015-03-17 Impact factor: 3.732
Authors: Radan Dzodic; Ivan Markovic; Momcilo Inic; Neven Jokic; Igor Djurisic; Milan Zegarac; Gordana Pupic; Zorka Milovanovic; Viktor Jovic; Nikola Jovanovic Journal: World J Surg Date: 2006-05 Impact factor: 3.352
Authors: Jason David Cundiff; Yi-Zarn Wang; Gregory Espenan; Thomas Maloney; Arthur Camp; Laura Lazarus; Alan Stolier; Randy Brooks; Bruce Torrance; Shawn Stafford; James P O'Leary; Eugene A Woltering Journal: Ann Surg Date: 2007-02 Impact factor: 12.969
Authors: Junxin Wang; Fang Chen; Santiago J Arconada-Alvarez; James Hartanto; Li-Peng Yap; Ryan Park; Fang Wang; Ivetta Vorobyova; Grant Dagliyan; Peter S Conti; Jesse V Jokerst Journal: Nano Lett Date: 2016-09-28 Impact factor: 11.189